Published: 11 April 2018
Author(s): Daniele Pastori, Alessio Farcomeni, Mirella Saliola, Francesco Del Sole, Pasquale Pignatelli, Francesco Violi, Gregory Y.H. Lip, ATHERO-AF Study Group
Issue: April 2018
Section: Original Article

Optimal time in therapeutic range (TTR) of vitamin K antagonists (VKAs) is crucial for cardiovascular events (CVEs) prevention in non-valvular atrial fibrillation (NVAF). The relationship between temporal changes of TTR and the incidence of CVEs has been poorly investigated. We investigated 1) temporal trends of TTR in a long-term follow-up of NVAF patients; 2) the incidence of CVEs according to changes of TTR.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.